

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | |
|--|--------------------------------|-------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | <i>Complete if Known</i> | |
| | Application Number | 09/754,775 |
| | Filing Date | January 4, 2001 |
| | First Named Inventor | David J. Grainger |
| | Group Art Unit | 1628 |
| | Examiner Name | Jennifer Kim |
| Sheet 1 of 3 | Attorney Docket No: 295.009US3 | |

US PATENT DOCUMENTS

| Examiner Initial * | USP Document Number | Publication Date | Name of Patentee or Applicant of cited Document | Filing Date If Appropriate |
|--------------------|---------------------|------------------|---|----------------------------|
|--------------------|---------------------|------------------|---|----------------------------|

FOREIGN PATENT DOCUMENTS

| Examiner Initial * | Foreign Document No | Publication Date | Name of Patentee or Applicant of cited Document | T 1 |
|--------------------|---------------------|------------------|---|-----|
|--------------------|---------------------|------------------|---|-----|

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

| | | |
|--------------------|--|-----|
| Examiner Initial * | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T 1 |
| | "Abstract for TOX-42 - 1,3-Diphenylguanidine (CASRN 102-06-7)", NTP Study Reports, (09/1995), 2 | |
| | "Application Serial No. 10/729,056, Response filed 02-23-10 to Non Final Office Action mailed 10-23-09", 18 pgs | |
| | "Application Serial No.10/729,056, Final Office Action mailed 06-15-10", 34 pgs | |
| | "Canadian Application Serial No. 2,223,595, Office Action dated 01-17-07", 2 pgs. | |
| | "Canadian Application Serial No. 2,223,595, Response filed 06-13-07 to Office Action dated 01-17-07", 6 pgs. | |
| | "European Application Serial No. 07021554.6, Communication dated 06-18-08", 2 pgs. | |
| | "European Application Serial No. 07021554.6, Response filed 07-09-08 to Communication dated 06-18-08", 23 pgs. | |
| | "Japanese Application Serial No. 9-502239, Decision of Final Rejection mailed 04-07-09", (w/ English Translation), 23 pgs. | |
| | "Japanese Application Serial No.2006-322111, Office Action Mailed 12/22/2009", (w/ English Translation), 8 pgs. | |
| | AGNUSDEI, D., et al., "Results of International Clinical Trials with Raloxifene", Ann Endocrino (Paris) PubMed, Abstract 60(3), (9/1999), 1 | |
| | BLUM, A., et al., "Selective estrogen receptor modulator effects on serum lipoproteins and vascular function in postmenopausal women and in hypercholesterolemic men.", Ann N Y Acad Sci., 949, (Dec., 2001), 168-74 | |
| | BUTTA, A., et al., "Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment", Cancer Res., 52(15), (Aug. 1, 1992), 4261-4 | |
| | CASTRO, MR, et al., "Clomiphene-induced Severe Hypertriglyceridemia and Pancreatitis", Mayo Clin. Proc., (11/1999), 1125-1128 | |
| | ERKKOLA, R., et al., "Bone Mineral Density and lipid Changes during 5 years of follow-up in a study of prevention of breast cancer with tamoxifen in healthy, high-risk pre- and post-menopausal women.", Breast Cancer Res Treat, 93(3), Department of Obstetrics and | |

EXAMINER**DATE CONSIDERED**

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | |
|---|--------------------------------|-------------------|
| <p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p> | <i>Complete if Known</i> | |
| | Application Number | 09/754,775 |
| | Filing Date | January 4, 2001 |
| | First Named Inventor | David J. Grainger |
| | Group Art Unit | 1628 |
| | Examiner Name | Jennifer Kim |
| Sheet 2 of 3 | Attorney Docket No: 295.009US3 | |

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

| Examiner Initial * | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T 1 |
|--------------------|---|-----|
| | Gynaecology, (Oct 2005), 277-87 | |
| | FRANK, R. N, "On the pathogenesis of diabetic retinopathy", Ophthalmology, 98(5), (May, 1991), 586-93 | |
| | GENNARI, L., "Lasoofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.", Drugs Today (Barc)., 42(6), (Jun., 2006), 355-67 | |
| | HARVEY, H. A, et al., "Toremifene: an evaluation of its safety profile", Breast, 15(2), (Nov 9, 2005), 142-57 | |
| | JORDAN, V. C, "Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.", J Med Chem., 46(7), (Mar. 27, 2003), 1081-111 | |
| | KELLEN, J. A, "Raloxifene", Curr Drug Targets, 2(4), (Dec., 2001), 423-5 | |
| | KOCKAYA, EA, et al., "Pathological and Biochemical Effects of Therapeutic and Supratherapeutic Doses of Celecoxib in Wistar Albino Male Rats", Drug Chem Toxicol, 2010 June 16 (Epub ahead of print) Abstract, (06/2010), 1 | |
| | KULLO, IFTIKHAR J., et al., "Conditional Risk Factors for Atherosclerosis", Mayo Clinic Proc.; 80(2), (02/2005), 219-230 | |
| | KUSAMA, M., et al., "Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrators", Breast Cancer Res Treat, 88(1), (Nov 2004), 9-16 | |
| | KUSAMA, M., et al., "Effects of Toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer", Breast Cancer Res Treat, 88(1), (Nov 2004), 1-8 | |
| | MULDER, H., et al., "The Effects of Idoxifene on Markers of Cardiovascular Risk in Osteopenic Postmenopausal Women", Cardiovascular Diseases in Women, Vol. 19, Univ. of Minn Bio-Medical Library, ISSN 0195 668X, Abstract Supplemental, (08/1998), 3 | |
| | MULDER, H., et al., "The effects of idoxifene on markers of cardiovascular risk in osteopenic postmenopausal women", European Heart Journal, 19(Suppl), (Aug., 1998), 237 | |
| | OKUBO, MICHIIITO, et al., "Effects of Probucol on Hypercholesterolemia in Renal Transplant Patients", Kidney International, 56,S229-S230, (1999), 4 | |
| | SATO, Y., "TGF-beta. and vascular disorders. Focusing on angiogenesis and atherosclerosis", Jikken Kagaku, 10(15), (1992), 1908-1912 | |
| | SMITH, MATTHEW R., et al., "Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study", Journal of Clinical Oncology, Vol. 26, No. 11, (04-10-2008), 1824-1829 | |
| | TARAS, T. L, et al., "Clinical pharmacokinetics of toremifene", Clin Pharmacokinet., 39(5), (Nov., 2000), 327-34 | |
| | VOGELVANG, T. E, et al., "Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications.", Treat Endocrinol., 3(2), (2004), 105-15 | |

EXAMINER**DATE CONSIDERED**

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | |
|--|--|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | <i>Complete if Known</i> Application Number 09/754,775 Filing Date January 4, 2001 First Named Inventor David J. Grainger Group Art Unit 1628 Examiner Name Jennifer Kim |
| Sheet 3 of 3 | |
| Attorney Docket No: 295.009US3 | |

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

| | | |
|--------------------|--|-----|
| Examiner Initial * | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T 1 |
| | WISEMAN, H., et al., "Tamoxifen inhibits lipid peroxidation in cardiac microsomes. Comparison with liver microsomes and potential relevance to the cardiovascular benefits associated with cancer prevention and treatment by tamoxifen.", Biochem Pharmacol., 45(9), (May 5,1993), 1851-5 | |

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached